PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028405
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028405
Tardive Dyskinesia Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of tardive dyskinesia therapeutics Market
The global tardive dyskinesia therapeutics market is witnessing steady growth driven by the increasing prevalence of neurological disorders and rising awareness regarding treatment options. The market was valued at USD 3.30 billion in 2025 and is projected to grow to USD 3.60 billion in 2026, reaching USD 7.22 billion by 2034, registering a CAGR of 9.10% during the forecast period. The United States dominated the market with an 88.23% share in 2025, supported by strong drug adoption, awareness initiatives, and advanced healthcare infrastructure.
Tardive dyskinesia (TD) is a drug-induced movement disorder caused by prolonged use of antipsychotic medications. It leads to involuntary movements of the face, tongue, and other body parts. Although there is no permanent cure, approved drugs such as valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO) help manage symptoms effectively.
Market Dynamics
Growth Drivers
The primary factor driving market growth is the rising prevalence of tardive dyskinesia, particularly among patients undergoing long-term treatment for schizophrenia, bipolar disorder, and other psychiatric conditions. Increased use of antipsychotic medications has significantly contributed to the growing patient pool.
Another key driver is the increase in government and organizational initiatives aimed at raising awareness about TD. Programs such as awareness weeks, patient support campaigns, and financial assistance initiatives are encouraging early diagnosis and treatment adoption.
Additionally, improved access to approved therapeutics and strong commercialization strategies by pharmaceutical companies are boosting market expansion. Awareness campaigns and direct-to-consumer outreach are further enhancing patient engagement.
Market Restraints
Despite positive growth, the market faces challenges such as limited R&D investment due to the relatively small patient population. Conducting large-scale clinical trials is difficult, which slows the development of new therapies.
Moreover, the high cost and complexity of drug development discourage pharmaceutical companies from investing heavily in this niche segment, potentially limiting innovation.
Market Trends
A major trend shaping the market is the increasing focus on awareness and patient engagement campaigns. Leading companies are investing in digital and television campaigns to educate patients and healthcare professionals about TD symptoms and treatment options.
Another notable trend is the growing adoption of VMAT2 inhibitors, particularly valbenazine, which continues to dominate due to its proven efficacy and strong presence in the U.S. market.
The market is also witnessing expansion into emerging regions, with regulatory approvals and partnerships enabling wider access to therapeutics in Asia Pacific and other regions.
Segmentation Analysis
By drug type, the market is segmented into valbenazine, deutetrabenazine, and others. The valbenazine segment holds the largest share, driven by high adoption rates and strong marketing efforts. The deutetrabenazine segment follows, supported by increasing approvals in countries such as China and Brazil.
By distribution channel, the market includes hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates, as these medications are primarily prescription-based and require clinical supervision.
Retail pharmacies also hold a significant share due to refill demand, while online pharmacies are expected to grow at the fastest rate, driven by increasing digital adoption and convenience.
Regional Insights
The United States leads the global market, with a value of USD 2.91 billion in 2025, increasing to USD 3.17 billion in 2026. Strong awareness programs, high prevalence rates, and favorable reimbursement policies are key growth drivers. The U.S. market is projected to reach USD 4.36 billion by 2030, highlighting its continued dominance.
Europe is expected to witness strong growth due to rising prevalence, estimated at 23.3% among psychiatric patients, and increasing efforts to introduce new therapeutics.
Asia Pacific is the second-largest market, driven by growing R&D activities and regulatory approvals. Countries such as China and Japan are focusing on expanding access to TD treatments.
The rest of the world, including Latin America and the Middle East & Africa, shows slower growth due to limited awareness and healthcare infrastructure.
Competitive Landscape
The market is highly concentrated, with key players such as Neurocrine Biosciences, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma Corporation, Luye Pharma Group, and SOM Biotech.
Neurocrine Biosciences leads the market with its flagship product INGREZZA, while Teva's AUSTEDO continues to gain traction. Companies are focusing on regulatory approvals, partnerships, and awareness campaigns to strengthen their market position.
Pipeline developments and clinical trials by emerging players are expected to introduce new treatment options in the future.
Conclusion
The tardive dyskinesia therapeutics market is poised for consistent growth, driven by rising disease prevalence, increasing awareness, and expanding access to treatment options. With market value projected to grow from USD 3.30 billion in 2025 to USD 7.22 billion by 2034, the industry offers promising opportunities for pharmaceutical companies. Although challenges such as limited R&D investment persist, ongoing innovation and supportive initiatives are expected to drive sustained market expansion.
Segmentation By Drug, Distribution Channel, and Region
By Drug * Deutetrabenazine
- Valbenazine
- Others
By Distribution Channel * Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region * U.S. (By Drug, By Distribution Channel)
- Europe (By Drug, By Distribution Channel, By Country/Sub-Region)
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific (By Drug, By Distribution Channel, By Country/Sub-Region)
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Rest of the World (By Drug, By Distribution Channel)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Tardive Dyskinesia, By Key Countries, 2025
- 4.2. Key Industry Developments
- 4.3. Pipeline Analysis
- 4.4. Economic Cost Burden for the Treatment of Tardive Dyskinesia
- 4.5. Regulatory & Reimbursement Scenario, By Key Regions
- 4.6. Impact of COVID-19 on the Market
5. Global Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug
- 5.1.1. Deutetrabenazine
- 5.1.2. Valbenazine
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.2.1. Hospital Pharmacies
- 5.2.2. Drug Stores & Retail Pharmacies
- 5.2.3. Online Pharmacies
- 5.3. Market Analysis, Insights and Forecast - By Country/Region
- 5.3.1. U.S.
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Rest of the World
6. U.S. Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug
- 6.1.1. Deutetrabenazine
- 6.1.2. Valbenazine
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.2.1. Hospital Pharmacies
- 6.2.2. Drug Stores & Retail Pharmacies
- 6.2.3. Online Pharmacies
7. Europe Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug
- 7.1.1. Deutetrabenazine
- 7.1.2. Valbenazine
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.2.1. Hospital Pharmacies
- 7.2.2. Drug Stores & Retail Pharmacies
- 7.2.3. Online Pharmacies
- 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 7.3.1. Germany
- 7.3.2. U.K.
- 7.3.3. France
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Rest of Europe
8. Asia Pacific Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug
- 8.1.1. Deutetrabenazine
- 8.1.2. Valbenazine
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.2.1. Hospital Pharmacies
- 8.2.2. Drug Stores & Retail Pharmacies
- 8.2.3. Online Pharmacies
- 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. Rest of Asia Pacific
9. Rest of the World Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug
- 9.1.1. Deutetrabenazine
- 9.1.2. Valbenazine
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.2.1. Hospital Pharmacies
- 9.2.2. Drug Stores & Retail Pharmacies
- 9.2.3. Online Pharmacies
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 10.2.1. Teva Pharmaceutical Industries Ltd.
- 10.2.1.1. Overview,
- 10.2.1.2. Products,
- 10.2.1.3. SWOT Analysis,
- 10.2.1.4. Recent Developments,
- 10.2.1.5. Strategies,
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Neurocrine Biosciences, Inc.
- 10.2.2.1. Overview,
- 10.2.2.2. Products,
- 10.2.2.3. SWOT Analysis,
- 10.2.2.4. Recent Developments,
- 10.2.2.5. Strategies,
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Mitsubishi Chemical Group Corporation.
- 10.2.3.1. Overview,
- 10.2.3.2. Products,
- 10.2.3.3. SWOT Analysis,
- 10.2.3.4. Recent Developments,
- 10.2.3.5. Strategies,
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. SOM BIOTECH
- 10.2.4.1. Overview,
- 10.2.4.2. Products,
- 10.2.4.3. SWOT Analysis,
- 10.2.4.4. Recent Developments,
- 10.2.4.5. Strategies,
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Luye Pharma Group
- 10.2.5.1. Overview,
- 10.2.5.2. Products,
- 10.2.5.3. SWOT Analysis,
- 10.2.5.4. Recent Developments,
- 10.2.5.5. Strategies,
- 10.2.5.6. Financials (Based on Availability)
- 10.2.1. Teva Pharmaceutical Industries Ltd.
List of Tables
- Table 1: Global Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 2: Global Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 3: Global Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Country/Region, 2021-2034
- Table 4: U.S. Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 5: U.S. Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 6: Europe Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 7: Europe Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 8: Europe Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
- Table 9: Asia Pacific Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 10: Asia Pacific Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 11: Asia Pacific Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
- Table 12: Rest of the World Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 13: Rest of the World Tardive Dyskinesia Therapeutics Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
List of Figures
- Figure 1: Global Tardive Dyskinesia Therapeutics Market Value Share (%), By Drug, 2025 & 2034
- Figure 2: Global Tardive Dyskinesia Therapeutics Market Value Share (%), By Distribution Channel, 2025 & 2034
- Figure 3: Global Tardive Dyskinesia Therapeutics Market Value Share (%), By Country/Region, 2025 & 2034
- Figure 4: U.S. Tardive Dyskinesia Therapeutics Market Value (USD billion), by Drug, 2025 & 2034
- Figure 5: U.S. Tardive Dyskinesia Therapeutics Market Value Share (%), by Drug, 2025
- Figure 6: U.S. Tardive Dyskinesia Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 7: U.S. Tardive Dyskinesia Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 8: Europe Tardive Dyskinesia Therapeutics Market Value (USD billion), by Drug, 2025 & 2034
- Figure 9: Europe Tardive Dyskinesia Therapeutics Market Value Share (%), by Drug, 2025
- Figure 10: Europe Tardive Dyskinesia Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 11: Europe Tardive Dyskinesia Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 12: Europe Tardive Dyskinesia Therapeutics Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
- Figure 13: Europe Tardive Dyskinesia Therapeutics Market Value Share (%), by Country/ Sub-Region, 2025
- Figure 14: Asia Pacific Tardive Dyskinesia Therapeutics Market Value (USD billion), by Drug, 2025 & 2034
- Figure 15: Asia Pacific Tardive Dyskinesia Therapeutics Market Value Share (%), by Drug, 2025
- Figure 16: Asia Pacific Tardive Dyskinesia Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 17: Asia Pacific Tardive Dyskinesia Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 18: Asia Pacific Tardive Dyskinesia Therapeutics Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
- Figure 19: Asia Pacific Tardive Dyskinesia Therapeutics Market Value Share (%), by Country/ Sub-Region, 2025
- Figure 20: Rest of the World Tardive Dyskinesia Therapeutics Market Value (USD billion), by Drug, 2025 & 2034
- Figure 21: Rest of the World Tardive Dyskinesia Therapeutics Market Value Share (%), by Drug, 2025
- Figure 22: Rest of the World Tardive Dyskinesia Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 23: Rest of the World Tardive Dyskinesia Therapeutics Market Value Share (%), by Distribution Channel, 2025
